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Abstract
Background: Recent researches demonstrate that pre-treatment with androgen could increase retrieved oocytes
number and clinical pregnancy rate in poor ovarian response (POR) patients. In view of gap junction intercellular
communication (GJIC) is important for follicular growth, and androgen plays an important role in improving
prognosis of POR patients, we speculate that androgen can increase the expression of connexin in follicle cells, and
improve ovarian microenvironment, thus can promote ovarian response. The objective of the research is to study
the effect of testosterone on connexin37 (Cx37) expression so as to provide theoretical basis for adding
testosterone in treatment of POR.
Methods: Cumulus-oocyte-cells (COCs) were collected from ICR mice ovaries, and were cultured in vitro for 48 h
and then treated with testosterone (T) at various concentration. To assess whether the effect of androgen on Cx37
expression is mediated through androgen receptor (AR) pathway, COCs were cultured in vitro with Flutamide
(androgen receptor antagonist). The expression of Cx37 was determined by western blot.
Results: The expression of Cx37 in COCs which were treated with testosterone was higher than that of control
group. There were significant differences (P < 0.001;<0.001;<0.001;<0.001). Cx37 increased with the elevated
testosterone concentrations. Cx37 was lower in androgen receptor antagonist group (2.57 ± 0.12) than the
corresponding testosterone concentrations group (4.42 ± 0.28). There were significant differences between two
groups (P < 0.001).
Conclusions: There was close relationship between gap junction protein and ovarian response, which suggested
that androgen could promote ovarian response by increasing the expression of Cx37 in follicle. Androgen plays an
important role in ovarian response through the AR pathway and non-AR pathway.
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Background
Poor ovarian response (POR), which is insensitive to
ovarian stimulation and results in fewer retrieved
oocytes, poorer quality embryos, and lower implantation
rate and clinical pregnancy rate, is considered to be one
of the most challenging tasks for clinicians in reproduct-
ive medicine [1]. POR is common in patients with di-
minished ovarian reserve (DOR), while the latter is
closely related to age. Androgen concentration in ovary
decreases sharply as age advances, so we speculate that
androgen concentration in follicular fluid of POR pa-
tients is lower than normal level. In view of the import-
ance of androgen to follicle recruitment, growth and
development, domestic and foreign reproductive centers
try to add androgen as an adjuvant to in-vitro
fertilization (IVF) treatment protocols in POR patients,
in order to increase both quantity and quality of oocytes
and embryos, and improve pregnancy outcomes. These
interventions include: (1) pretreatment with transdermal
testosterone; (2) pretreatment with dehydroepiandroster-
one (DHEA); (3) addition of aromatase inhibitors; (4)
addition of recombinant luteinizing hormone (LH); (5)
addition of human chorionic gonadotrophin (hCG) during
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ovarian stimulation [2]. Commonly used androgen prepa-
rations include transdermal testosterone or oral DHEA.
The mechanism of action of androgen in improving ovar-
ian response is unclear. Recent researches report that
there is a direct and indirect effect of androgen on follicle
development. According to the two cell/two gonado-
trophin theory, androgen plays an important role in ensur-
ing adequate follicular steroidogenesis. Produced
primarily by the theca cells, it acts as a substrate for the
aromatase activity of the granlosa cells, and converts to es-
trogen (estradiol and estrone), sequentially plays a role in
follicle growth [3]. This is called indirect regulation effect
of androgen. Recent researches report that androgen can
also regulate follicle development directly through various
mechanisms [4].
Numerous studies have shown that oocyte is in avas-
cular environment, so normal folliculogenesis relies on
the bidirectional talk between any two of granulosa cells,
cumulus cells and oocytes [5]. As a form of direct path-
way, GJIC plays an important role in folliculogenesis and
steroidogenesis [6]. Gap junctions are clusters of inter-
cellular channels composed of two compatible hemi-
channels (connexin, Cx) in the adjacent cells plasma
membrane, which permit the rapid exchange of inor-
ganic ions, second messengers and small molecules from
cell to cell. Our previous studies have found that a sig-
nificant decrease of connexin in cumulus cells is closely
related to POR. In view of GJIC is vitally important for
follicular recruitment, growth and mature, and androgen
plays an important role in improving prognosis of POR
patients, so we speculate that androgen can increase the
expression of connexin in follicle cells, and improve
ovarian microenvironment, thus can promote ovarian
response.
Current researches about the effect of androgen on
gap junction protein mainly focus on polycystic ovary
syndrome (PCOS), but the results are not consistent.
Cheng et al. found that high androgen reduces con-
nexin43 expression and impairs GJIC between human
granulosa cells. High androgen may impair folliculogen-
esis and in turn lead to ovulatory dysfunction in PCOS
patients [7]. But the result of Rabih et al. was in contrast.
The study presented that Cx43 levels were up-regulated
in PCO rat ovaries [8]. The researches were aimed at the
effect of high concentration of androgen on gap junction
protein, and the results still needed further discussion.
However, to the best of our knowledge, there has been
no report regarding the effect of the different levels with
right amount androgen on Cx37 expression in COCs.
The varieties and distributions of connexin in mouse
ovary are in accordance with human. Cx43 is mainly lo-
calized to the membrane of granulosa cells and cumulus
cells, while Cx37 is mainly expressed at the membrane
of oocyte in COCs. In this research, we investigated the
differences of Cx37 of COCs which were cultured with
different concentrations of androgen among physio-
logical level range, and we explored the mechanism of
androgen on ovarian response, and provided theoretical
basis for adding androgen in treatment of POR in
clinical.
The choice of testosterone concentration in culture
medium in vitro is mainly on the basis of physiology
concentration of androgen in follicle fluid and cytoxicity
test in vitro culture of granulosa cells. Researches sug-
gest that the normal concentration of testosterone in fol-
licle fluid is between 10−8M and 10−7M [9]. Another
research about the cytoxicity test in vitro culture of
granulosa cells with different concentrations of testoster-
one suggests that growth inhitibion ratio is about 50%
with 10−4M testosterone. Therefore, the concentration
of testosterone in in vitro culture should be lower than
10−4M. We treated COCs with testosterone of the
equivalent of physiological concentration in follicular
fluid (10−7M), low concentration (10−9M, 10−11M), high
concentration (10−5M) after comprehensive evaluation
from physiology concentration and cytotoxicology test.
To assess whether the effect of androgen on connexin
was mediated through the AR pathway, we cultured
COCs with 10−7M testosterone and 10−6M Flutamide
(androgen receptor antagonist).
Methods
Twenty six-to-eight-week-old female ICR mice were fed
in the barrier environment at animal center of Peking
University First Hospital. All animal care requirements
were fulfilled, and animals were given food and water ad
libitum. After a week, ICR mice were given pregnant
mare serum gonadotropin (PMSG, 10 IU per mouse) in
order to stimulate ovulation. 48 h later, ICR mice were
put to death through dislocating cervical vertebra. The
ovaries were removed and washed in sterile condi-
tions. COCs were isolated from the excised ovaries
by follicle puncture using needle in culture medium
with dissecting microscope. The culture medium was
collected and the cells were sedimented by centrifuga-
tion at 500 g for 5 min at 4 °C. The COCs were
placed in 4-well cell culture plates with 495 μL cul-
ture medium at a seeding density of 20–30 COCs per
well. COCs were cultured in a humidified incubator
(5 % CO2) at 37 °C in order to separate from the
hormone environment in vivo for 48 h. Then, COCs
were treated with 10−11mol/L testosterone (T) (dis-
solved by glycerin, 5 μL), 10−9mol/L T, 10−7mol/L T,
10−5mol/L T, 10−0mol/L T (blank control group), 10
−7mol/L T and 10−6mol/L Flutamide for 24 h. The
COCs and culture medium were collected respectively
and sedimented by centrifugation at 500 g for 5 min.
The culture medium was discarded and the COCs
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were harvested after being washed with cold
phosphate-buffered saline (PBS).
Total proteins extracted from COCs were analyzed by
western blot for connexin37. Cells were homogenized
into RIPA buffer supplemented with protease inhibitors
(100:1) for 30 min, and then centrifuged at 3000 g for
20 min. The supernatant was transferred to a new cen-
trifuge tube for western blot. After determination of pro-
tein content by the bicinchoninic acid (BCA) protein
assay method, 30 μg proteins were separated by 10% so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto nitrocellulose mem-
branes. After blocked with 5% skimmed milk for 1 h, the
membranes were incubated with primary goat anti-
mouse Cx37 antibody (1:200, Santa Cruz, USA) for 1 h
at room temperature and overnight at 4 °C. After
washed three times in Tris-buffered saline (TBS)-0.1%
Tween 20, the membranes were incubated with monkey
anti-goat IgG conjugated with horseradish peroxidase
(HRP) (1:5000, ZSGB-BIO, China) for 1 h at room
temperature. The membranes were washed again like
above and the immunoreactivity was examined by the
enhanced chemiluminescence (ECL) system. As a con-
trol for normalization, the membranes were re-probed
for internal control, β-actin (1:200, Santa Cruz, USA).
Films were scanned, and the optical density of the bands
was measured with AlphaEaseFC. The relative quantity
of Cx37 was determined with reference to β-actin. Final
data were expressed as the mean of results in three inde-
pendent experiments performed at different time points.
All analyses were performed with Software Package for
Social Sciences (SPSS) version 10.0 for windows. All data
were expressed as mean ± standard deviation (SD). Com-
parison between two groups was done with independent
sample T-test, and comparison among multi samples
was done with variance analysis, and intergroup multiple
comparison was done with Bonferroni. P < 0.05 was con-
sidered as statistically significant.
Results
Influence of different concentrations of testosterone on
Cx37 expression
To study the mechanism of androgen improving ovarian
response, our research examined the levels of expression
of Cx37 in COCs which were cultured with different
levels of testosterone for 24 h in vitro.
Western blot results suggested that Cx37 could be de-
tected in COCs of all groups. The results were shown in
Fig. 1. The expression of Cx37 in COCs which were
treated with 10−11mol/L T (3.55 ± 0.10), 10−9mol/L T
(3.92 ± 0.21), 10−7mol/L T (4.42 ± 0.28), 10−5mol/L T
(4.93 ± 0.22) was higher than that of blank control group
(1.59 ± 0.29). There were significant differences (P <
0.001; <0.001; <0.001; <0.001).
The expression of Cx37 in COCs increased with the
elevated testosterone concentrations, and there was
significantly difference in four groups of being cul-
tured with testosterone (P < 0.05). Bonferroni analysis
suggested that the expression of Cx37 in COCs which
was treated with 10−11 mol/L T was significantly
lower than those of being treated with 10−9mol/L T,
10−7mol/L T, 10−5mol/L T (P = 0.002; <0.001; <0.001).
The expression of Cx37 in COCs which was treated
with 10−9mol/L T was significantly lower than those
of being treated with 10−7mol/L T, 10−5mol/L T (P <
0.001; <0.001). The expression of Cx37 in COCs
which was treated with 10−7mol/L T was significantly lower
than that of being treated with 10−5mol/L T (P < 0.001).
The effect of androgen receptor antagonist (Flutamide)
on Cx37 expression
To assess whether the effect of androgen on Cx37 ex-
pression was mediated through androgen receptor (AR)
pathway, COCs were cultured in vitro with testosterone
and Flutamide. The physiological concentration of tes-
tosterone in follicle fluid is 10−7M, so we cultured COCs
with 10−7M testosterone and 10−6M Flutamide (10-fold
excess above that of testosterone).
Western blot results suggested that Cx37 was de-
tected in COCs in both groups. The expression of
Cx37 in COCs which were treated with 10−7mol/L T
and 10−6mol/L Flutamide (2.57 ± 0.12) was lower than
that of only treated with 10−7mol/L T (4.42 ± 0.28).
Fig. 1 Expression of Cx37 in COCs in different concentrations of
testosterone. The expression of Cx37 which were treated with T was
higher than that of blank control group. Cx37 increased with the
elevated testosterone concentrations, and there was significantly
difference in four groups of being cultured with testosterone
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There were significant differences between two groups
(P < 0.001). The results were shown in Fig. 2.
Discussion
POR is one of the most challenging tasks for clinicians
in reproductive medicine. Several interventions includ-
ing adjusting stimulation protocols, using oral contra-
ceptive, adding growth hormone have been proposed to
improve the POR outcome. Unfortunately, the effect of
these interventions is limited. Recent researches with en-
couraging results demonstrate that pre-treatment with
androgen, such as DHEA and trans-dermal testosterone,
could increase retrieved oocytes number and clinical
pregnancy rate in DOR and POR patients. Casson et al.
first reported the benefits of DHEA supplementation for
improving the ovarian response and retrieved oocytes
number [10]. Since then, a few controlled studies includ-
ing a randomized controlled study, but with small sam-
ple size, have subsequently reported benefits of DHEA
supplementation to improve ovarian response and IVF
outcome [11]. Nevertheless, controversy still exists as
to whether these protocols improved cycle outcome
[12, 13]. A recent world-wide survey has shown that
over a quarter of reproduction centers add DHEA as
an adjuvant to IVF treatment protocols in women
with DOR or POR. Despite widespread use of andro-
gen, clinical evidence as well as knowledge regarding
underlying mechanisms of androgen on improvement
of ovarian response is still limited.
Recent researches report that there is a direct and in-
direct effect of androgen on follicle development.
According to the two cell/two gonadotrophin theory, an-
drogen plays an important role in ensuring adequate fol-
licular steroidogenesis. Produced primarily by the theca
cells, it acts as a substrate for the aromatase activity of
the granlosa cells, and converts to estrogens (estradiol
and estrone), sequentially plays a role in follicle growth
[3]. This is called indirect regulation effect of androgen.
Recent researches report androgen can also regulate fol-
licle development directly through various mechanisms
[4]. The mechanisms include the following several
aspects: (1) androgen can increase one or more critical
follicle growth factors concentration such as insulin-like
growth factor-1 (IGF-1), growth differentiation factor-9
(GDF-9) in follicular fluid during the early stage of fol-
licular development, which are known to have positive
effect on follicular development and oocyte quality
[14, 15]; (2) androgen can augment granulosa cell fol-
licle stimulating hormone receptor (FSHR) expression
and improve follicle sensibility to FSH during the
antral follicle stage [16]; (3) androgen via the AR
pathway inhibits the expression of PTEN, and phos-
phorylate Akt proteins by phosphatidyl inositol 3-
kinase (PI3K)-Akt signaling pathways, thus induces
primordium follicle activation [17]; (4) androgen can
up-regulate the expression of AR, promote granulosa
cell proliferation and inhibit apoptosis [18].
Our previous studies have found that a significant de-
creased of connexin in cumulus cells is closely related to
POR. In view of gap junctional intercellular communica-
tion is vitally important for follicular recruitment,
growth and mature, and androgen plays an important
role in improving prognosis of POR patients, we specu-
late that androgen can increase the expression of
connexin in follicle cells, and improve ovarian micro-
environment, thus promote ovarian response. To test
this speculation, we treated COCs with testosterone of
the equivalent of physiological concentrations in follicu-
lar fluid (10−7M), low concentration (10−9M, 10−11M),
high concentration (10−5M) and blank control group.
The results suggested that compared to control group,
testosterone-treated groups demonstrated an increasing
amount of Cx37 protein in a dose–dependent manner.
Combining with the preliminary study, our research sug-
gested that adding a certain amount of androgen can im-
prove the expression of connexin which is located the
surface of oocytes and somatic cells in ovary, strengthen
material and information communication among cells,
improve ovarian micro-environment, thus improve ovar-
ian response.
However, the mechanism of action of androgen on af-
fecting the expression of connexin is unclear. AR ap-
pears on the surface of graunlosa cells when follicles
Fig. 2 Expression of Cx37 in COCs in androgen receptor antagonist.
The expression of Cx37 which were treated with 10−7 mol/L T and
10−6mol/L Flutamide was lower than that of treated with 10−7 mol/L
T. There were significant differences between two groups
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start to improve, and the expression increases with fol-
licle development. The expression of AR increases to
peak on the surface of preantral follicle and small antral
follicle, then begins to decline, and nearly cannot be de-
tected on the surface of preovulatory follicle [19, 20].
The variation of AR expression suggests that the func-
tion of androgen is different at the different stages of fol-
licle development. Androgen can promote follicle
recruitment and small antral follicle development
through direct action in the early stage of follicle devel-
opment; while most of androgen translates into estrogen
and plays an indirect role in the follicle development, yet
there is some direct effect. In this study, the expression
of Cx37 in mouse COCs which were treated with andro-
gen receptor antagonist was lower than the correspond-
ing androgen group. The result suggested that androgen
via the AR pathway played an important role in Cx37
expression. Further studies are required to understand
the androgen-induced GJIC dependent signaling path-
ways mediating ovarian response.
Conclusions
This study suggested that androgen can improve the ex-
pression of connexin37 which is located the surface of
oocytes and somatic cells in ovary in a dose–dependent
manner. There was close relationship between gap junc-
tion protein and ovarian response, which suggested that
androgen could promote ovarian response by increasing
the expression of Cx37 in follicle. Androgen via the AR
pathway can promote the expression of connexin in
COCs, strengthen material and information communica-
tion between oocytes and somatic cells, improve ovarian
micro-environment, and thus improve ovarian response.
The mechanism provides theoretical basis for adding an-
drogen in treatment of POR in clinical. But the problem
about rational use of time and dose of androgen still
needs large sample clinical research.
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